retatrutide diabetes trial produces up to 30.3% weight loss in Phase 3 ⚠️ BEWARE OF RETATRUTIDE SOLD

Strategy Matters More Than the Drug: Both medications can lead to significant weight loss, but without a plan (strength training, nutrition, tapering off), users risk muscle loss, metabolic slowdown, and regaining weight later.

Files Download Full Text (382 KB) Description Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant clinical benefit in managing diabetes mellitus type 2 (DM2), facilitating chronic weight loss, and potentially improving obstructive sleep apnea

Better sleep reduces the severity of obstructive sleep apnea (New England Journal of Medicine, 2024)

This agile approach to supply chain risks has helped us develop flexible solutions to mitigate adverse impacts

In a randomised controlled trial with over 1800 participants comparing tirzepatide to semaglutide, the tirzepatide group reported more serious adverse events (5-7% VS 3%) and higher discontinuation rates due to adverse events (6-8.5% VS 4%)

cerebral metabolic rate for glucose